Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Chloroquine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.88 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.80 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.50 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.50 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.50 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | NSD1 | Q96L73 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.88 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.88 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.88 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.88 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.88 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.88 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.88 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.88 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.88 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloroquine SCHEMBL2785005 | 1.00 | HSD17B10 (1.00) | HSD17B10KDM4EMAPTNSD1CHRM2 | |
| Chloroquine SCHEMBL40827 | 1.00 | HSD17B10 (1.00) | HSD17B10KDM4EMAPTNSD1CHRM2 | |
| Chloroquine SCHEMBL40829 | 1.00 | HSD17B10 (1.00) | HSD17B10KDM4EMAPTNSD1CHRM2 | |
| Chloroquine SCHEMBL16702898 | 1.00 | HSD17B10 (1.00) | HSD17B10KDM4EMAPTNSD1CHRM2 | |
| Chloroquine SCHEMBL29383276 | 1.00 | HSD17B10 (1.00) | HSD17B10KDM4EMAPTNSD1CHRM2 | |
| Chloroquine SCHEMBL29013905 | 0.99 | KDM4E (0.98) | HSD17B10KDM4EMAPTNSD1CHRM2 | |
| Chloroquine SCHEMBL27925391 | 0.99 | HSD17B10 (0.98) | HSD17B10KDM4EMAPTNSD1CHRM2 | |
| Chloroquine SCHEMBL6410710 | 0.96 | KDM4E (0.93) | HSD17B10KDM4EMAPTNSD1CHRM2 | |
| Chloroquine SCHEMBL28713274 | 0.94 | HSD17B10 (0.89) | HSD17B10KDM4EMAPTNSD1CHRM2 | |
| Chloroquine SCHEMBL13684873 | 0.94 | HSD17B10 (0.89) | HSD17B10KDM4EMAPTNSD1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4515 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| CN-118373411-B | Preparation method and analysis application of humifuse euphorbia herb biomass carbon quantum dots | 广东药科大学 | 2026-05-15 | — | — | CN | claimed |
| CN-122031417-A | Pharmaceutical composition for enhancing immunotherapeutic effect of colon cancer | 天津市肿瘤医院（天津医科大学肿瘤医院） | 2026-05-15 | — | — | CN | claimed |
| CN-122006821-A | H-Co with hollow core-shell tubular structure3O4@CoMn-LDH catalyst and preparation method and application thereof | 聊城大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| EP-4722231-A1 | BIOSYNTHESIS METHOD FOR BROAD-SPECTRUM ANTIVIRAL POLYPEPTIDE | Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| US-12527766-B2 | Methods of treating acute coronary syndrome using 3,3′-diindolylmethane | BOULDER BIOSCIENCE LLC (US) | 2026-01-20 | — | — | US | claimed |
| EP-4673157-A2 | COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | Persephone Biosciences, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| WO-2000021504-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2000-04-20 | — | — | WO | claimed |
| EP-0935523-A4 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GEN MILLS INC (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0935523-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GENERAL MILLS, INC. (US) | 1999-08-18 | — | — | EP | claimed |
| EP-0925308-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | Micrologix Biotech, Inc. (CA) | 1999-06-30 | — | — | EP | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| WO-1998007745-A9 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | — | 1998-04-23 | — | — | WO | claimed |
| WO-1998007745-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | MICROLOGIX BIOTECH, INC. (CA) | 1998-02-26 | — | — | WO | claimed |
| WO-1997037680-A1 | MACROMOLECULAR COMPLEXES FOR DRUG DELIVERY | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1997-10-16 | — | — | WO | claimed |
| US-5278173-A | Method of inhibiting the activity of human immunodeficiency virus (HIV) in vivo | DAVIS MICHAEL H (US) | 1994-01-11 | — | — | US | claimed |
| US-5021426-A | Mixture with chloroquine, hydroxychloroquine, amodiaquine, mefloquine or salts thereof | MERCK & CO., INC. (US) | 1991-06-04 | — | — | US | claimed |